Principal Investigator - Professor Mosepele Mosepele, MD, MSc
Study Status: The study opened on January 22, 2020 and accrual completed on January 27, 2021. Participant follow up ongoing.
- Describe the prevalence and longitudinal changes in albuminuria over a 12-month period among treated HIV-infected adults overall, and in relation to the use of ACEI/ARB.
- Describe the association between albuminuria and inflammation among treated HIV-infected adults overall and in relation to the use of ACEI/ARB.
- Create a human bio-repository and HIV-CVD outcomes clinical registry for the study of long-term clinical outcomes of albuminuria.
Study Design: This is an observational prospective study in a high HIV prevalence clinical setting.
Study Population: Study inclusion criteria include HIV-infected adults 21 years or older, being on ART for 6 months or more, and willingness to provide urine sample. The study excludes patients who are not able to produce urine or are on renal replacement therapy.
Study Duration: 60 months
Study Results: Study ongoing
Sponsor: European and Developing Countries Clinical Trials Partnership (EDCTP).